Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ release

Area of Science:

• Cardiology
• Pharmacology
• Molecular Biology

Background:

• Ventricular tachyarrhythmias in heart failure are often triggered by spontaneous Ca(2+) waves, also known as store overload-induced Ca(2+) release (SOICR).
• The precise mechanisms behind the antiarrhythmic efficacy of carvedilol, a widely used beta blocker, remain incompletely understood.

Purpose of the Study:

• To elucidate the antiarrhythmic mechanisms of carvedilol in heart failure.
• To investigate carvedilol's effect on SOICR and the cardiac ryanodine receptor (RyR2).
• To develop novel therapeutic strategies for heart failure by combining SOICR inhibition and beta-blockade.

Main Methods:

• Utilized electrophysiological studies to assess carvedilol's impact on SOICR and RyR2 function.
• Developed and tested a novel carvedilol analog (VK-II-86) with selective SOICR inhibitory properties.
• Evaluated the efficacy of VK-II-86 and carvedilol in preventing stress-induced ventricular tachyarrhythmias in a mouse model.

Main Results:

• Carvedilol was the only tested beta blocker that effectively suppressed SOICR by reducing RyR2 open duration.
• A novel analog, VK-II-86, demonstrated potent SOICR inhibition with minimal beta-blocking activity.
• VK-II-86 significantly prevented ventricular tachyarrhythmias in RyR2-mutant mice, especially when combined with other beta blockers.

Conclusions:

• Carvedilol's antiarrhythmic effect likely stems from its dual action: beta-blockade and direct suppression of SOICR via RyR2 modulation.
• Targeting SOICR, in addition to beta-adrenergic blockade, offers a promising approach for developing personalized antiarrhythmic therapies.
• The development of agents like VK-II-86 allows for tailored titration of antiarrhythmic strategies based on individual patient needs.